bioAffinity Technologies Reports Q1 CyPath Lung Diagnostic Unit Sales Up 146% YoY

bioAffinity Technologies reported a 146% year-over-year increase in sales for its Q1 CyPath Lung Diagnostic unit. The noninvasive diagnostic technology is gaining traction in a U.S. market valued at $3.58 billion for pulmonary nodule management and lung cancer survivor surveillance. The company's flow cytometry combined with AI technology is expected to enhance lung cancer risk assessment and nodule management.